Eli Lilly and Company $LLY Shares Purchased by Mainstay Capital Management LLC ADV

Key Points

• Mainstay Capital Management LLC ADV increased its stake in Eli Lilly and Company by 104.3%, owning 2,948 shares worth approximately $2.3 million by the end of the second quarter.
• Recent insider purchases include Gabrielle Sulzberger, who bought 117 shares at $641.18 each, and Daniel Skovronsky, who acquired 1,000 shares at $634.40, indicating confidence in the company's future performance.
• Eli Lilly has seen analyst upgrades, with Guggenheim raising its price target to $948.00 and maintaining a "buy" rating, while the stock has an average target price of $948.56.

Mainstay Capital Management LLC ADV boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 104.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,948 shares of the company's stock after acquiring an additional 1,505 shares during the period. Mainstay Capital Management LLC ADV's holdings in Eli Lilly and Company were worth $2,297,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Hobbs Wealth Management LLC lifted its holdings in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC lifted its holdings in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after acquiring an additional 12 shares during the last quarter. O Brien Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares during the last quarter. Ascent Capital Management LLC lifted its holdings in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after acquiring an additional 12 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners lifted its holdings in Eli Lilly and Company by 2.7% in the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after acquiring an additional 13 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Guggenheim upped their price target on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a "buy" rating in a report on Wednesday. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an "overweight" rating in a report on Thursday. Morgan Stanley reduced their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research note on Friday, October 3rd. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $948.56.

Eli Lilly and Company Price Performance

NYSE LLY opened at $854.40 on Friday. The company has a 50 day simple moving average of $740.99 and a 200-day simple moving average of $766.49. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $808.66 billion, a price-to-earnings ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.